Each year approximately 50,000 people in the U.S. will become infected with HIV. To prevent infection, especially in high risk groups, the FDA approved pre-exposure prophylaxis (PrEP), and in 2014 the USPHS/CDC created clinical practice guidelines for the use of PrEP. This presentation discusses the recent USPHS/CDC guidelines in addition to ways clinicians can facilitate open patient-provider dialog, education, and engagement in PrEP. This presentation also discusses universal HIV-screening, in addition to establishing risk for HIV acquisition, determining PrEP eligibility, assessing patients’ PrEP readiness, and counseling patients on PrEP efficacy, safety, and treatment-adherence.